EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression
By: Han Wei, Jia Zhao, Hongmei Wang, Lihong Guo, Yanhong Liu, Chuntao Wang, Liang Yang, Zhi Qi, Wencong Tian, Lei Cao and Yang Gao
References
- Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-89. doi: 10.1097/00000478-199904000-00002
- Xu Y, Peng XL, East MP, Mccabe IC, Stroman GC, Jenner MR, et al. Tumorintrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches. Cancer Discov 2025; 15: 346-62. doi: 10.1158/2159-8290.CD-23-1480
- Venkataraman V, George S, Cote GM. Molecular advances in the treatment of advanced gastrointestinal stromal tumor. Oncologist 2023; 28: 671-81. doi: 10.1093/oncolo/oyad167
- Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45. doi: 10.1016/S0022-3565(24)38879-2
- Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9. doi: 10.1016/j.humpath.2008.06.025
- Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265-72. doi: 10.1001/jama.2012.347
- Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57: 259-70. doi: 10.1111/j.1365-2559.2010.03624.x
- Xi H, Wu X, Wei B, Chen L. Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol 2012; 47: 785-94. doi: 10.1007/s00535-012-0549-4
- Li M, Yang C, Liu X, Yuan L, Zhang F, Wang M, et al. EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways. Cancer Lett 2016; 383: 195-203. doi: 10.1016/j.canlet.2016.10.004
- Nasri B, Inokuchi M, Ishikawa T, Uetake H, Takagi Y, Otsuki S, et al. High expression of EphA3 (erythropoietin-producing hepatocellular a3) in gastric cancer is associated with metastasis and poor survival. BMC Clin Pathol 2017; 17: 8. doi: 10.1186/s12907-017-0047-y
- Surawska H, Ma PC, Salgia R. The role of ephrins and eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419-33. doi: 10.1016/j.cytogfr.2004.09.002
- Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 2018; 34: i884-i90. doi: 10.1093/bioinformatics/bty560
- Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 2019; 37: 907-15. doi: 10.1038/s41587-019-0201-4
- Liao Y, Smyth GK, Shi W. Featurecounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-30. doi: 10.1093/bioinformatics/btt656
- Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550. doi: 10.1186/s13059-014-0550-8
- Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (N Y) 2021; 2: 100141. doi: 10.1016/j.xinn.2021.100141
- Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res 2025; 53: D672-D7. doi: 10.1093/nar/gkae909
- Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30. doi: 10.1093/nar/28.1.27
- Park I, Lee H. EphB/ephrinb signaling in cell adhesion and migration. Mol Cells 2015; 38: 14-9. doi: 10.14348/molcells.2015.2116
- Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, et al. Roles of ephrinb ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13: 295-306. doi: 10.1101/gad.13.3.295
- Anderton M, van der Meulen E, Blumenthal MJ, Schafer G. The role of the eph receptor family in tumorigenesis. Cancers (Basel) 2021; 13: 206. doi:10.3390/cancers13020206
- Chen J. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res 2012: 114: 1-20. doi: 10.1016/B978-0-12-386503-8.00001-6.
- Kandouz M. The eph/ephrin family in cancer metastasis: communication at the service of invasion. Cancer Metastasis Rev 2012; 31: 353-73. doi: 10.1007/s10555-012-9352-1
- Talia M, Cirillo F, Spinelli A, Zicarelli A, Scordamaglia D, Muglia L, et al. The ephrin tyrosine kinase A3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. J Exp Clin Cancer Res 2023; 42: 122-64. doi: 10.1186/s13046-023-02747-5
- Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-80. doi: 10.1038/nrc2806
- Nievergall E, Lackmann M, Janes PW. Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci 2012; 69: 1813-42. doi: 10.1007/s00018-011-0900-6
- Offenhauser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, et al. EphA3 pay-loaded antibody therapeutics for the treatment of glioblastoma. Cancers (Basel) 2018; 10: 519. doi: 10.3390/cancers10120519
- Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of ephb2 and ephb4 in breast carcinoma. Pathol Oncol Res 2004; 10: 26-33. doi: 10.1007/BF02893405
- Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006; 169: 279-93. doi: 10.2353/ajpath.2006.050889
- Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JMM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008; 118: 64-78. doi: 10.1172/JCI33154
- Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Retraction note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004; 23: 1448-56. doi: 10.1038/sj.onc.1207247
Language: English
Page range: 416 - 426
Submitted on: May 6, 2026
Accepted on: Jun 4, 2026
Published on: Sep 7, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Han Wei, Jia Zhao, Hongmei Wang, Lihong Guo, Yanhong Liu, Chuntao Wang, Liang Yang, Zhi Qi, Wencong Tian, Lei Cao, Yang Gao, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.